Introduction {#Sec1}
============

Influenza infection has been recently defined as a risk factor of invasive aspergillosis \[[@CR12], [@CR26]\]. Influenza can cause severe pneumonia and acute respiratory distress syndrome (ARDS) \[[@CR17], [@CR31], [@CR35]\]. Respiratory bacterial superinfection of influenza represents a common complication with high mortality \[[@CR15], [@CR18], [@CR25], [@CR29], [@CR30]\]. Bacterial pathogens superinfecting influenza pneumonia have changed over time probably as a function of both different hosts and influenza strains. These include *Haemophilus influenzae*, *Streptococcus pyogenes*, *Staphylococcus aureus* and *Streptococcus pneumoniae* \[[@CR18]\]*. S. pneumoniae* was the most common pathogen in the 1918 pandemic \[[@CR29]\] and *S. aureus* emerged as another frequent co-pathogen during the 2009/2010 H1N1 pandemic \[[@CR25], [@CR30]\]. High prevalence of *Pseudomonas aeruginosa* superinfection has been reported in intensive care unit (ICU) patients \[[@CR15], [@CR16]\]. Superinfection with *Aspergillus* spp. has been increasingly described since the 2009/2010 influenza pandemic \[[@CR2], [@CR10], [@CR13], [@CR36]\] associated with even higher mortality (33--67%) \[[@CR7], [@CR11], [@CR26], [@CR32], [@CR36]\]. IAA is independent of influenza type (A or B \[[@CR20], [@CR26]\]) and also affects immunocompetent hosts. Between 10--23% of influenza patients in the ICU \[[@CR26], [@CR32], [@CR36]\], less frequently in North America (7.2%) \[[@CR27]\] and 32% of immunocompromised influenza patients have been reported to have IAA \[[@CR26]\]. Predictors of IAA, poor outcome and mortality in influenza patients in the ICU remain unknown. Since no data on IAA was available from Switzerland, we retrospectively analysed all patients with severe influenza infection needing treatment in two large Swiss ICUs during the 2017/2018 influenza season with regard to predictors of IAA, mortality and poor outcome.

Methods {#Sec2}
=======

Study design, participants and outcomes {#Sec3}
---------------------------------------

In this retrospective cohort study, sixteen ICUs of tertiary hospitals in Switzerland were asked if they had observed cases of IAA and severe influenza and routinely looked for IAA based on clinical suspicion with galactomannan and fungal cultures in BAL; only two of them met the criteria (Cantonal Hospital of St. Gallen and University Hospital of Geneva). All adults (≥ 18 years) with confirmed influenza infection during the 2017/2018 influenza season (December 2017--April 2018) admitted to the ICU for ≥ 24 h of those centres were included. Patients whose influenza diagnosis occurred after the discharge from the ICU were excluded. Influenza infection was diagnosed by polymerase chain reaction (PCR) from nasopharyngeal swab, sputum or bronchoalveolar lavage (BAL). Patients were identified from the ICU databases, infectious diseases and hospital epidemiology databases in order to improve identification of patients and reduce reporting bias. The study was approved by the local ethics committees (EKOS 2018-01994). There was no funding.

Endpoints {#Sec4}
---------

The primary aim was to identify predictors of IAA in critically ill patients with influenza infection. Secondary aims were to detect predictors of mortality and poor outcome of severe influenza infection. Poor outcome was defined as a composite of ICU length of stay (LOS) ≥ 7 days, need of extracorporeal membrane oxygenation (ECMO), invasive ventilation for ≥ 7 days or in-hospital death.

ARDS was diagnosed according to the Berlin criteria \[[@CR3], [@CR4]\].

Outcome definitions {#Sec5}
-------------------

A.Definitions

IAA was defined by clinical, radiological and mycological criteria according to the modified criteria of IAA by Schauwvlieghe et al. and Blot et al. (Supplementary table [1](#MOESM1){ref-type="media"}) \[[@CR5], [@CR26]\]. Records of all IAA patients were reviewed and consensus was achieved by investigators from both centres whether criteria of IAA were fulfilled. The Platelia assay "Aspergillus Ag" (Biorad) was used to detect GM.

Respiratory superinfection was defined as (I) detection of clinically relevant bacterial or fungal pathogen in respiratory specimens or positive blood cultures that was treated with antibiotics or antifungals, respectively, (II) a positive pneumococcal urinary antigen, *Pneumocystis jirovecii* antigen in BAL or positive GM in serum or BAL (Table [1](#Tab1){ref-type="table"} in the Appendix). Other superinfection included all respiratory superinfections, bacteraemia, catheter-associated infections and *Clostridioides difficile* colitis.

Organ supportive therapies were defined as need of renal replacement therapy, vasoactive support, invasive mechanical ventilation and ECMO.

Statistical analysis {#Sec6}
--------------------

Continuous variables were assessed by *t* tests or Mann-Whitney *U* tests as appropriate. For categorical values, comparison was done by Fisher's exact test. Missing data were not imputed. A two-sided *p* value \< 0.05 was considered as statistically significant. Given the small number of each outcome, only the univariate but not the multivariable analyses are reported. Data analysis was performed with SAS (version 9.3, SAS Institute Inc., Cary, NC, USA) and R core team (2017, R foundation for statistical computing, Vienna, Austria).

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

Of 91 patients identified from the databases, 10 were excluded (5 patients per centre) and 81 were included and analysed. Median follow-up time was 17 days. Nine patients had IAA (11%). There were no statistically significant differences in baseline characteristics between patients with and without IAA (Table [1](#Tab1){ref-type="table"} in the Appendix). Immunosuppressive diseases were uncommon in both groups. During hospitalization, corticosteroids were initiated in half of all influenza patients (78% vs. 46% in IAA and non-IAA, *p* = 0.14). 5/37 (13.5%) patients with influenza A had IAA and 4/44 (9%) with influenza B (*p* = 0.55).

Duration of influenza symptoms before diagnosis of influenza was significantly longer in those with IAA (median duration 9 days (interquartile range (IQR) 5--14) vs. 5 days (IQR 4--8) in non-IAA, *p* = 0.03), whereas there was no difference in duration of symptoms until hospitalization (median duration 8 days (IQR 4--11) in IAA and 4 days (IQR 3--8) in non-IAA, *p* = 0.11). IAA symptoms started after a median of 3 days after ICU admission. IAA was diagnosed after a median of 7 days after ICU admission and 11 days after first symptoms of influenza (IQR 3--8 and 10--18 days respectively). GM was measured in 33% of all patients (89% in IAA and 26% in non-IAA, *p* \< 0.001). GM was positive in 1 of 19 (5.3%) patients in non-IAA and 7 of 8 (88%) samples with IAA (*p* \< 0.001). All patients with positive GM had antibiotics prior to GM testing, as had 14 of 16 (87.5%) patients with a negative GM (*p* = 0.52). Two patients with IAA and negative GM had therapy with voriconazole started on the same day as GM testing was performed. It cannot be excluded that treatment was started before BAL was performed which could have caused in a false-negative test result. Eight of 9 patients with IAA had radiologic infiltrates and 4 nodules. There were no positive cultures of *Aspergillus* spp. in non-IAA patients but growth of *Aspergillus* spp. in 8 (89%) patients with IAA, mainly *Aspergillus fumigatus* (7 of 8 patients).

Severity and outcome of illness {#Sec9}
-------------------------------

Organ supportive therapies and complications were more frequent in IAA patients than in non-IAA patients (Table [2](#Tab2){ref-type="table"} in the Appendix). Median duration of antibiotic treatment (16 vs. 6.5 days), invasive mechanical ventilation (13 vs. 0 days), vasoactive support (7 vs. 0 days), hospital-LOS (40 vs. 15 days) and ICU-LOS (17 vs. 3 days) were significantly extended in IAA compared with non-IAA patients (Fig. [1](#Fig1){ref-type="fig"}). The length of stay in the ICU was significantly elevated in IAA patients (Fig. [2](#Fig2){ref-type="fig"}). Treatment with antivirals (oseltamivir with or without zanamivir) was initiated in all patients with IAA and 93% of non-IAA patients (*p* = 1.0). Mold-active antifungal treatment was initiated in 16 patients (8 patients each with IAA and non-IAA because of presumed IAA during hospitalisation). Median duration of antifungal treatment was 10 days (IQR 1.5--25.5) in IAA. Antifungal treatment was stopped when diagnostics were negative in those without IAA. Corticosteroids were used during hospitalisation in 60.5% of patients (89% in IAA vs. 20.5% in non-IAA, *p* = 0.12) and before influenza diagnosis in 3 of 9 of patients with IAA and in 16 of 72 of patients without IAA (33% vs. 22%, *p* = 0.7). All patients with IAA had poor outcome compared with 36% of non-IAA patients (*p* \< 0.001).Fig. 1Duration of antibiotic use, organ supportive therapies and LOS - length of stayFig. 2Kaplan Meier curve on the probability of ICU stay in IAA and non-IAA patients

Co-infections {#Sec10}
-------------

IAA patients had more bacterial or fungal (other than due to *Aspergillus* spp.) respiratory superinfections (67% vs. 28%, *p* = 0.002). Other infectious complications were catheter-related bloodstream infections and oropharyngeal and oesophageal candidiasis. *Aspergillus* (*n* = 9) was the most frequent respiratory co-pathogen in influenza patients. Other common pathogens were *S. aureus*, *S. pneumoniae*, *S. pyogenes* and Gram-negative bacteria (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Number of isolated pathogens in patients with influenza

Predictors of mortality and poor outcome {#Sec11}
----------------------------------------

Invasive mechanical ventilation, vasoactive support, ECMO, any complication, respiratory and any superinfection were significantly associated with mortality and poor prognosis (Table [3](#Tab3){ref-type="table"} in the Appendix).

Discussion {#Sec12}
==========

Our study has several main findings. IAA is a severe and relatively frequent complication affecting 11% of patients with influenza treated in two Swiss ICUs. Aspergillus represented the most frequent respiratory co-infection of influenza in this cohort. Patients with influenza were most commonly superinfected with *Aspergillus* spp. despite lacking classical risk factors of invasive aspergillosis. In our study, all patients with IAA had poor outcome and needed more frequently and longer organ supportive therapies such as invasive mechanical ventilation, renal support and vasopressors. Further risk factors for poor outcome were respiratory superinfections.

IAA patients in our study did not have classical risk factors for aspergillosis such as underlying immunosuppressive disease, hematologic malignancies, solid organ or haematopoietic stem cell transplantation or immunosuppressive medications before hospitalisation. Instead, severe influenza infection was frequently their unique risk factor. The occurrence of IAA independent of classical risk factors of invasive aspergillosis has been previously reported \[[@CR7], [@CR13], [@CR28], [@CR34]\]. One study showed higher mortality in immunosuppressed patients with IAA in comparison to immunocompetent patients \[[@CR26]\]. Reported risk factors for IAA are male sex and corticosteroid therapy prior to the influenza infection \[[@CR26], [@CR36]\]. The latter might explain the relatively high number of patients with obstructive lung diseases \[[@CR2]\]. We identified the need for prolonged organ supportive therapies in the ICU as a predictor for IAA. The length of ICU was significantly elevated. Because of small sample size, a competitive risk analysis was not performed. Since IAA can occur in the absence of underlying diseases, requirement of vasoactive therapy, rapidly deteriorating respiratory failure and progressive multiple organ failure might be useful alerts for ICU physicians of IAA in severely ill patients with influenza.

Surprisingly, in our cohort, *Aspergillus* was identified as the most common respiratory superinfecting pathogen in influenza infection. *Aspergillus* was seen in 22% of all respiratory co-pathogens in our analysis in contrast to 7.2--8.7% of positive cultures from respiratory specimen reported in the literature \[[@CR15], [@CR16]\]. Bacterial pathogens are more frequently reported as influenza co-pathogens than *Aspergillus* \[[@CR15], [@CR16]\]. Bacterial co-infections in influenza showed increasing trends over the last years (from 11.4% in 2009 to 23% in 2015) while *Aspergillus* isolation from culture was relatively stable at \~ 7% in a study of Spanish ICUs \[[@CR15]\]. Bacterial respiratory superinfection was even more common in our analysis (35%). Concurrently, *S. aureus* and *S. pneumoniae* were frequently observed in our analysis as were Gram-negative bacteria including *P. aeruginosa*. Respiratory co-infections were significantly associated with mortality in our univariate analysis. Association of co-infection with *S. aureus*, *P. aeruginosa* or *Aspergillus* spp. with mortality has been described \[[@CR15]\]. Therefore, influenza patients at risk for respiratory superinfection need to be identified and early diagnostics and treatment need to be implemented.

The increasing reports of IAA could be due to greater awareness and lower threshold for more and more sensitive diagnostics or indeed an increasing prevalence of this fungal disease. IAA was first reported in 1952 \[[@CR1]\] but only received attention of a wider audience in the last decade after the 2009 influenza H1N1 pandemic \[[@CR2], [@CR10], [@CR13], [@CR16]\]. An influencing factor could be the wide use of corticosteroids \[[@CR16]\] and neuraminidase inhibitors for influenza infections in the ICU. In our analysis, many influenza patients received corticosteroids during hospitalization (60.5%) with a non-significant difference between patients with or without IAA, despite data showing increased mortality of influenza pneumonia with corticosteroid use \[[@CR21], [@CR37]\]. Corticosteroid use has been associated with aspergillosis independently of influenza infection \[[@CR6], [@CR14], [@CR19], [@CR23]\] and corticosteroid use prior to influenza infection has been associated with IAA \[[@CR26], [@CR36]\]. Furthermore, experimental in vitro studies and studies in mice indicate that neuraminidase inhibition decreases immune response by impaired cytokine production in response to *Aspergillus* spp. This effect is also seen with corticosteroid and neuraminidase treatment \[[@CR33]\]. This implies that therapy of influenza with neuraminidase inhibitors and corticosteroids might increase susceptibility and predispose to mold infection in influenza. We hypothesize that a greater use of neuraminidase inhibitors since the 2009 influenza pandemic could have contributed to the emergence of IAA. Alternatively, as recently reported in a retrospective cohort study from Alberta, Canada, from 2014 to 2019, different influenza seasons may be associated with varying rates of IAA. In their study, Schwartz et al. identified a considerably higher rate in the most recent 2018/2019 season \[[@CR27]\].

GM values in BAL in our study were slightly lower than in previous reports (67-88% \[[@CR7], [@CR26], [@CR27]\] or even 97% among patients with underlying respiratory diseases \[[@CR24]\]), which may have been in part due to the possibility that 2 patients with negative BAL GM might have received voriconazole prior to diagnostic testing.

Interestingly, two patients, who met our criteria for IAA, were not or only briefly treated with antifungal therapy. Both patients survived. We cannot definitely exclude colonisation with *Aspergillus* because no histological examination was done. Elevated GM, long duration of invasive ventilation (11 and 15 days) and ICU LOS (17 and 29 days) argue in favour of IAA in these two patients. These two patients could have had a less severe form of IAA. Importantly, 8 of 9 patients had cultural evidence of *Aspergillus* spp., arguing against false-positive GM results. IAA is a relatively new field of research with few clinical studies and no prospective data. Because IAA patients do not fulfil EORTC criteria for invasive fungal disease \[[@CR8]\] new diagnostic criteria were proposed \[[@CR5], [@CR22], [@CR26]\]. These criteria do not allow for graduation of classification as with EORTC criteria (possible, probable, confirmed IA), have not been evaluated prospectively and diagnosis of IAA remains difficult. Furthermore, optimal treatment duration remains a matter of debate. IAA likely represents a heterogeneous entity and a benign course of disease could be possible although previous studies suggest otherwise with reported mortality of 33--47%, and 67% in Taiwan \[[@CR7], [@CR11], [@CR26], [@CR32], [@CR36]\]. Mortality in our cohort was in concordance with previous reports in non-immunocompromised patients (33%) \[[@CR26]\].

Our study has a few limitations. Firstly, it is limited by the retrospective design. We cannot rule out that cases of aspergillosis have been missed but the rarity of positive GM tests or growth of *Aspergillus* in cultures in the non-IAA group and the poor outcome in IAA which would lead to diagnostic work-up suggest otherwise. However, the true incidence of IAA might have been even higher. Secondly, two patients without IAA did not fulfil mycological IAA criteria but received long antifungal therapy for presumed IAA during hospitalisation and had extended LOS on the ICU. Therefore, differences concerning outcomes might have been underestimated between groups. Furthermore, the generalisability is limited by small sample size. However, patients' characteristics and mortality are concordant with previous studies on IAA. Finally, owing to the retrospective design, it was not always possible to distinguish whether a complication was predisposing to IAA or a complication of IAA. Of note, both hospitals are the only major tertiary care centres in their area. Since all patients who fulfilled the listed criteria were included in the study, we consider recruitment bias unlikely.

In conclusion, IAA represents an underappreciated complication of influenza infection with severe morbidity and mortality in Swiss ICUs. Only 2 out of 16 Swiss ICUs participated in the study because screening and diagnosis of IAA were rarely done which is evidence for the poor awareness of this disease. While bacterial superinfection was frequent in influenza patients in the ICU, *Aspergillus* was even more common. The need for organ support therapy might serve as a predictor of IAA. Because of frequency and severity of disease, greater awareness of IAA is needed and lower thresholds for diagnostic testing (GM, bacterial and fungal cultures from BAL) and treatment should be implemented in the ICU, especially in patients requiring organ support therapies. A multicentre study including all university hospitals in Switzerland and two tertiary care centres is on its way to confirm our study outcome and raise awareness of this severe entity. Prospective studies are urgently needed to evaluate proposed diagnostic criteria, characterize clinical outcomes, identify patients at risk of IAA and define optimal antiviral and antifungal treatment and duration.
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Table 1Baseline characteristics of patients and diagnosticsNon-IAA (*n* = 72)IAA (*n* = 9)*p* valueCharacteristics of patients  Age (year, median, (iqr))68 (58.0, 75.2)58 (57.0, 64.0)0.21  Female sex (%)35 (48.6)3 (33)0.49  SAPS II (median, (iqr))42.5 (39.0, 66.0)44 (39.0, 66.0)0.5  Influenza A (%)32 (44.4)5 (55.6)0.73  COPD (%)25 (34.7)2 (22.2)0.71  Bronchial asthma (%)3 (4.1)2 (22.2)0.09  Any immunosuppressive condition\* (%)15 (20.8)1 (11.1)0.86  Haematologic malignancy (%)8 (11.3)00.59  Solid cancer (%)4 (5.6)1 (11.1)0.45  Immunosuppressive drugs (%)12 (16.7)00.34  Neutropenia at influenza diagnosis (%)1 (1.4)01  Lymphopenia at influenza diagnosis (%)43 (59.7)7 (77.8)0.47  Diabetes mellitus (%)18 (25.0)3 (33.3)0.43  Renal failure (%)16 (22.2)3 (33.3)0.43  Cardiovascular disease (%)29 (40.3)3 (33.3)1  Other comorbidities (%)31 (43.1)2 (22.2)0.29  No known comorbidities (%)7 (9.7)1 (11.1)1Diagnostics  GM measured serum/BAL (%)5/17 (26.4\*\*)6/8 (88.9\*\*\*)\< 0.001  Elevated GM in serum (% of GM)1 (20)2 (33.3)0.70  Elevated GM in BAL (% of GM)05 (62.5)\< 0.001  Cultural evidence of *Aspergillus* spp. in BAL, TA or sputum (%)08 (88.9)\< 0.001  Histopathological evidence of aspergillosis-1 (11.1)-  Findings on CXR or CT scan (%)    No infiltrate15 (20.9)00.28    Unilateral infiltrate10 (13.9)2 (22.2)0.80    Bilateral infiltrates40 (55.6)6 (66.7)0.79    Nodules5 (6.9)4 (44.4)0.01*y* years, *iqr* interquartile range, *COPD* chronic obstructive pulmonary disease, *IAA* influenza-associated aspergillosis, *Non-IAA* influenza infection without aspergillosis, *GM* galactomannan, *BAL* bronchoalveolar lavage, *TA* tracheal aspirate*SAPS II* simplified acute physiology score, estimates mortality in ICU patients \[[@CR9]\]. Neutropenia is neutrophil count ≤ 0.5 G/l and lymphopenia is lymphocyte count ≤ 1 G/l\*Any immunosuppressive condition included solid organ or haematologic stem cell transplantation, haematologic malignancy or any immunosuppressive drugs including corticosteroids before diagnosis of influenza\*\*Total of 19 patients with GM measured (3 cases had GM measured in BAL (cut-off, optical density (OD) ≥ 1.0) and serum (cut-off, OD ≥ 0.5 \[[@CR26]\])\*\*\*Total of 8 patients (6 cases had GM measured in BAL and serum)

Table 2Organ supportive therapies, complications and outcomesNon-IAA\
(*n* = 72 (89%))IAA\
(*n* = 9 (11%))*p* valueOrgan supportive therapy  Invasive mechanical ventilation (%)30 (41.7)9 (100)\< 0.001  Renal replacement therapy\* (%)9 (12.5)4 (44.4)0.03  vv-ECMO (%)10 (13.9)2 (22.2)0.62  Vasoactive support (%)32 (44.4)8 (88.9)0.01Complications and outcomes  Any complication\*\* (%)43 (62.0)7 (77.8)0.48  ARDS (%)15 (20.8)5 (55.6)0.04  Respiratory superinfection (%)20 (27.8)9 (100)\< 0.001  ICU mortality (%)11 (15.3)3 (33.3)0.18  In-hospital mortality (%)13 (18.1)3 (33.3)0.37  Combined poor outcome (%)26 (36.1)9 (100)\< 0.001\*Includes haemodialysis and diafiltration\*\*Any complication includes ARDS, cardiogenic shock, stroke, multi-organ failure, delirium and other complications*Vv-ECMO* veno-venous extracorporeal membrane oxygenation, *ARDS* acute respiratory distress syndrome, *ICU* intensive care unit, *IAA* influenza-associated aspergillosis, *Non-IAA* influenza infection without aspergillosis

Table 3Predictors of mortality and poor prognosis (univariate analysis)ParametersMortalityPoor outcomeOR (95% CI)*p* valueOR (95% CI)*p* valueInfluenza A1.2 (0.3--4)0.83 (1.1--8.8)*0.02*IAA2.2 (0.3--12)0.5--*\< 0.001*Antifungal therapy2 (0.5--9)0.332 (4--1451)*\< 0.001*Invasive mechanical ventilation4.1 (1.1--20)*0.03*17 (5--64)*\< 0.001*Vasoactive support23 (3.2--1035)*\< 0.001*20 (6--86)*\< 0.001*Renal replacement therapy\*2 (0.5--8)0.310 (1.9--98)*0.002*vv-ECMO3.6 (0.8--17)*0.05*--*\< 0.001*Any complication5 (1--49)*0.04*3.4 (1.2--11)*0.02*ARDS3 (0.8--11)0.122 (4.6--219)*\< 0.001*Respiratory superinfection11 (2.7--52)*\< 0.001*6 (2--19)*\< 0.001*Any superinfection\*\*6.6 (1.7--32)*0.002*6 (2--18)*\< 0.001*Multi-organ failure--*0.007*--0.15Significant *p* values are indicated in italics\*Includes haemodialysis and diafiltration\*\*Any complication includes ARDS, cardiogenic shock, stroke, multi-organ failure, delirium and other complications-- not applicable due to 0 in the denominator*Vv-ECMO* veno-venous extracorporeal membrane oxygenation, *ARDS* acute respiratory distress syndrome. *IAA* influenza-associated aspergillosis, *OR* odds ratio, *CI* confidence interval
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